BofA Son Acadia (ACAD): 'our focus continues to be on the reacceleration of the Daybue launch in Rett syndrome'
Tweet Send to a Friend
BofA Securities analyst Tazeen Ahmad reiterated a Neutral rating and $27.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
